Reported Q: Q3 2024 Rev YoY: +1.3% EPS YoY: +8.1% Move: +0.76%
MettlerToledo
0K10.L
$1 383.16 0.76%
Exchange LSE Sector Healthcare Industry Medical Pharmaceuticals
Q3 2024
Published: Nov 8, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for 0K10.L

Reported

Report Date

Nov 8, 2024

Quarter Q3 2024

Revenue

954.54M

YoY: +1.3%

EPS

9.94

YoY: +8.1%

Market Move

+0.76%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $954.54M up 1.3% year-over-year
  • EPS of $9.94 increased by 8.1% from previous year
  • Gross margin of 58.1%
  • Net income of 211.52M
  • "Not available in the provided data." - N/A
0K10.L
Company 0K10.L

Executive Summary

Executive Summary:
- Revenue for QQ3 2024 rose modestly year over year to $954.5 million, representing a YoY increase of approximately 1.28% and a QoQ increase of about 0.82%. Gross profit was $554.2 million with a gross margin of ~58.1%, while operating income reached $278.3 million (operating margin ~29.2%). Net income was $211.5 million, translating to a net margin of roughly 22.2% and diluted EPS of $9.94–$10.01 for the period.
- The company produced robust cash flow, generating $254.7 million of net cash from operating activities and free cash flow of about $233.2 million. Capital expenditures were modest at roughly $21.4 million, supporting a strong FCF profile that funded aggressive stock buybacks (~$212.5 million) and other financing activity, with net debt of approximately $2.01 billion and an interest-coverage ratio near 13x.
- Balance sheet remains debt-heavy with total liabilities of ~$3.47 billion against total assets of ~$3.32 billion and negative shareholders’ equity (~$0.155 billion). The liquidity metrics show a current ratio near 1.01, underscoring modest short-term liquidity. The company’s leverage and negative equity render the balance sheet sensitive to capital market conditions, but strong profitability and cash generation provide a mitigating buffer.
- Management commentary (from the provided data) is not included in the transcript; no earnings call transcript was supplied in the input. As a result, quotes from management could not be incorporated directly. The analysis below integrates the disclosed financials with industry context and historical performance to inform the investment outlook.

Key Performance Indicators

Revenue
Increasing
954.54M
QoQ: 0.82% | YoY: 1.28%
Gross Profit
Decreasing
554.22M
58.06% margin
QoQ: 1.23% | YoY: -0.95%
Operating Income
Increasing
278.33M
QoQ: 4.67% | YoY: 886 301.27%
Net Income
Increasing
211.52M
QoQ: -4.64% | YoY: 4.90%
EPS
Increasing
10.01
QoQ: -3.93% | YoY: 8.10%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 1,029.70 10.57 +7.9% View
Q2 2025 983.22 9.77 +3.9% View
Q1 2025 883.74 7.84 -4.6% View
Q4 2024 1,045.13 11.96 +11.8% View
Q3 2024 954.54 9.94 +1.3% View